Publications by authors named "Neil Berinstein"

Claim this Profile
R
Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors.
Jorge J Castillo, Francesco Autore, Neil L Berinstein, Andrew R Branagan, Meletios A Dimopoulos

Semin Hematol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics of relapsed/refractory diffuse large B-cell lymphoma patients with durable responses to maveropepimut-S, pembrolizumab, and cyclophosphamide: Long-term follow-up from the SPiReL trial.
Arjun Pandey, Kim Roos, Yidi Jiang, Kathryn Mangoff, Gail Klein, Neil L Berinstein

EJHaem· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intensity of survivin expression linked to features of aggressive relapsed/refractory diffuse large B-cell lymphoma.
Sila Usta, Alexandra Misura, Iran Rashedi, Irina Amitai, Kim Roos, Neil L Berinstein

Leuk Lymphoma· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-L1 expression predicts efficacy in the phase II SPiReL trial with MVP-S, pembrolizumab, and low-dose CPA in R/R DLBCL.
Irina Amitai, Kim Roos, Iran Rashedi, Yidi Jiang, Kathryn Mangoff, Neil L Berinstein

Eur J Haematol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience.
Adam Suleman, Jiajia Liu, Lisa K Hicks, Adi Klil Drori, Michael Crump, Neil Berinstein

Haematologica· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response.
Genevieve M Weir, Olga Hrytsenko, Marianne M Stanford, Neil L Berinstein, Mohan Karkada

Oncoimmunology· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autologous stem cell transplant and combination immunotherapy of rituximab and interferon-α induces prolonged clinical and molecular remissions in patients with follicular lymphoma.
Liam Smyth, Rena Buckstein, Nancy Pennell, Rashmi Weerasinghe, Matthew C Cheung, Neil Berinstein

Br J Haematol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum-derived carcinoembryonic antigen (CEA) activates fibroblasts to induce a local re-modeling of the extracellular matrix that favors the engraftment of CEA-expressing tumor cells.
Aws Abdul-Wahid, Marzena Cydzik, Nicholas W Fischer, Aaron Prodeus, John E Shively, Neil L Berinstein

Int J Cancer· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers.
Gregory T Wolf, Jeffrey S Moyer, Michael J Kaplan, Jason G Newman, James E Egan, Neil L Berinstein

Onco Targets Ther· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of newly diagnosed high-risk and intermediate-risk follicular lymphoma with Y ibritumomab tiuxetan in a phase II study.
Neil L Berinstein, Nancy M Pennell, Rashmi Weerasinghe, Rena Buckstein, Eugenia Piliotis

Hematol Oncol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
Genevieve M Weir, Olga Hrytsenko, Tara Quinton, Neil L Berinstein, Marianne M Stanford

J Immunother Cancer· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased immune infiltration and chemokine receptor expression in head and neck epithelial tumors after neoadjuvant immunotherapy with the IRX-2 regimen.
Neil L Berinstein, Michael McNamara, Ariane Nguyen, James Egan, Gregory T Wolf

Oncoimmunology· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells.
Diane M Da Silva, Andrew W Woodham, Paul H Naylor, James E Egan, Neil L Berinstein

J Interferon Cytokine Res· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients.
Neil L Berinstein, Mohan Karkada, Amit M Oza, Kunle Odunsi, Jeannine A Villella

Oncoimmunology· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis.
Lee Mozessohn, Matthew C Cheung, Michael Crump, Rena Buckstein, Neil Berinstein

Leuk Lymphoma· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival of patients with transformed lymphoma in the rituximab era.
Hany R Guirguis, Matthew C Cheung, Eugenia Piliotis, David Spaner, Neil L Berinstein

Ann Hematol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.
Ronald Levy, Kristen N Ganjoo, John P Leonard, Julie M Vose, Ian W Flinn, Neil L Berinstein

J Clin Oncol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic vaccines and cancer: focus on DPX-0907.
Mohan Karkada, Neil L Berinstein, Marc Mansour

Biologics· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
Hany R Guirguis, Matthew C Cheung, Mervat Mahrous, Eugenia Piliotis, Neil Berinstein

Br J Haematol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients.
Neil L Berinstein, Mohan Karkada, Michael A Morse, John J Nemunaitis, Gurkamal Chatta

J Transl Med· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen.
Neil L Berinstein, Gregory T Wolf, Paul H Naylor, Lorraine Baltzer, James E Egan

Cancer Immunol Immunother· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma.
Theresa L Whiteside, Lisa H Butterfield, Paul H Naylor, James E Egan, John W Hadden, Neil L Berinstein

Cancer Immunol Immunother· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining the critical hurdles in cancer immunotherapy.
Bernard A Fox, Dolores J Schendel, Lisa H Butterfield, Steinar Aamdal, James P Allison, Neil Berinstein

J Transl Med· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peptide Based Vaccine Approaches for Cancer-A Novel Approach Using a WT-1 Synthetic Long Peptide and the IRX-2 Immunomodulatory Regimen.
Paul H Naylor, James E Egan, Neil L Berinstein

Cancers (Basel)· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma.
Thorsten U Vogel, Lucian Visan, Belma Ljutic, Beata Gajewska, Judy Caterini, Neil L Berinstein

J Immunother· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis